Insider Buying: Profound Medical Corp. (TSE:PRN) Director Purchases 14,200 Shares of Stock

Profound Medical Corp. (TSE:PRN) Director Arun Menawat Dr. acquired 14,200 shares of the company’s stock in a transaction on Friday, March 14th. The stock was purchased at an average cost of C$10.09 per share, for a total transaction of C$143,319.75.

Profound Medical Stock Up 0.9 %

Shares of TSE:PRN traded up C$0.09 during trading hours on Tuesday, reaching C$9.75. The stock had a trading volume of 304 shares, compared to its average volume of 5,674. Profound Medical Corp. has a 1 year low of C$7.90 and a 1 year high of C$15.75. The firm’s 50 day moving average is C$9.95 and its 200-day moving average is C$10.52. The company has a debt-to-equity ratio of 20.05, a quick ratio of 14.98 and a current ratio of 6.12. The stock has a market capitalization of C$205.45 million, a price-to-earnings ratio of -5.06 and a beta of 0.81.

About Profound Medical

Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum.